Bladder cancer research presented by Dana-Farber's Guru Sonpavde, MD at ASCO #GU21: Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC) Abstract 453 So what we did is a retrospective study in which we look at patients, all patients who got a PD one or L one and a better, um, in patients with in metaphoric urethral carcinoma. And what we did is then look at whether concurrent, angiotensin converting enzyme inhibitors or angiotensin receptor blockers a r Bs. I had an impact on tumor regression or not, we looked at the Dana Farber data set. As the Discovery Data set, we looked at the Moffitt Cancer data set as a validation dataset. So we had two hundred and seventy eight patients in the Dana Farber data set, and we had a hundred and one patients in the market data set. So overall, a fairly large retrospective study if you combine these benefits of two hundred and seventy nine patients. So the bottom line is that there was a statistically significant association of concurrent ace inhibitors, or air BCE Uh, with a p one l one any better in metastatic curatorial customer on a multi variance analysis in the Dana Farber dataset. Now, when we looked at the market data set, the association looked robust in the multi variant. Remember, that's a little bit smaller data set a hundred and one patients, so the P value was nearly significant but did not quite achieve. It was point Oh five four. However, we think that the signal here of the association of the ACE inhibitors and ARBs with thirty one and one in addition to improve the tumor regression is robust.